Russian Heart Failure Journal 2012year High blood serotonin levels – marker of CHF or depression?


To access this material please log in or register

Register Authorize
2012/№1

High blood serotonin levels – marker of CHF or depression?

Kirillova V. V., Prosviryakov E. Yu.

Keywords: 5-hydroxyindoleacetic acid, depression, blood, noradrenaline, serotonin, CHF

DOI: 10.18087/rhfj.2012.1.1647

Relevance. Role of serotonin in the pathogenesis of depression and CHF has not been completely studied to date. Objective. Estimate blood concentrations of serotonin, 5‑hydroxyindoleacetic acid (5‑HIAA), 5 НТ / 5‑HIAA, noradrenaline in CHF patients depending on occurrence of depression. Materials and methods. Blood concentrations of serotonin, 5‑HIAA, noradrenaline were estimated by HPLC electrochemical detection in patients with CHF FCI–III (New-York classification), with and without depression. Control group comprised male patients of the same age as in the study groups, who had no CVDs in the past history and by echoCG data. Results. CHF patients had higher blood concentrations of serotonin, 5‑HIAA in comparison with the control group (1540.4±240.98 nmol / l and 100.3±6.34 nmol / l versus control 375.19±158.08 nmol / l; 25.77±3.18 nmol / l), (p<0,01). Noradrenaline concentration in CHF patients did not differ from the control (2.74±0.81 nmol / l versus control 3.97±0.31 nmol / l). Serotonin, 5‑HIAA, noradrenaline concentrations in patients did not differ depending on occurrence of depression. Conclusion. Thus, increased serotonin concentration, its metabolism, missing noradrenaline concentration changes in CHF patients with and without depression.
  1. Barefoot JC, Helms MJ, Mark DB et al. Depression and long-term morta­lity risk in patients with coronary artery disease. Am J Cardiol. 1996;78 (6):613–617.
  2. Оганов Р. Г. Материалы симпозиума «Депрессия в кардиологии: больше, чем фактор риска», Российский национальный конгресс кардиологов. – М. 2003. – С. 1–4.
  3. Thomas SA, Friedmann E, Khatta M et al. Depression in patients with heart failure: physiologic effects, incidence, and relation to mortality. AACN Clin Issues. 2003;14 (1):3–12.
  4. Musselman DL, Evans DL, Nemeroff CB. The relationship of depression to cardiovascular disease: epidemiology, biology, and treatment. Arch Gen Psychiatry. 1998;55 (7):580–592.
  5. Meltzer H. Serotonergic dysfunction in depression. Br J Psychiatry Suppl. 1989; (8):25–31.
  6. Lambert G, Johansson M, Agren H et al. Reduced brain norepinephrine and dopamine release in treatment-refractory depressive illness: evidence in support of the catecholamine hypothesis of mood disorders. Arch Gen Psychiatry. 2000;57 (8):787–793.
  7. Van de Kar LD. Neuroendocrine aspects of the serotonergic hypothesis of depression. Neurosci Biobehav Rev. 1989;13 (4):237–246.
  8. Cleare AJ. Reduced whole blood serotonin in major depression. Depress anxiety. 1997;5 (2):108–111.
  9. Sarrias MJ, Cabre P, Martinez E et al. Relationship between serotoninergic measures in blood and cerebrospinal fluid simultaneously obtained in humans. J Neurochem. 1990 Mar; 54 (3):783–786.
  10. Brown ES, Varghese FP, McEwen BS. Association of depression with medi­cal illness: does cortisol play a role? Biol Psychiatry. 2004;55 (1):1–9.
  11. Maas JW, Katz MM, Koslow SH et al. Adrenomedullary function in depressed patients. J Psychiatr Res. 1994;28 (4):357–367.
  12. Cote F, Fligny C, Fromes Y et al. Recent advances in understanding serotonin regulation of cardiovascular function. Trends Mol Med. 2004;10 (5):232–238.
  13. Кириллова В. В., Нигматуллина Р. Р., Джорджикия Р. К. и др. Повышение концентрации серотонина, 5‑ОИУК в плазме крови у пациентов с легочной гипертензией, развившейся при патологии митрального клапана. Бюллетень экспериментальной биологии и медицины. 2009;147 (4): 388–390.
  14. Nigmatullina RR, Kirillova VV, Jourjikiya RK et al. Disrupted serotonergic and sympathoadrenal systems in patients with chronic heart failure may serve as new therapeutic targets and novel biomarkers to assess severity, progression, and response to treatment. Cardiology. 2009;113 (4):277–286.
  15. Puri VK, Verma M, Saxena AK, Shanker K. Platelet serotonergic mechanisms in ischaemic heart disease. Thromb Res. 1990;57 (3):445–451.
  16. Нигматуллина Р. Р., Кириллова В. В., Джорджикия Р. К. и др. Состояние симпато-адреналовой системы у больных хронической сердечной недостаточностью. Клиническая медицина. 2009;87 (4):32–36.
  17. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severitymeasure. J Gen InternMedю 2001;16 (9): 606–613.
  18. Lowe B, Spitzer RL, Grafe K et al. Comparative validity of three screening questionnaires for DSM–IV depressive disorders and physicians’ diagnoses. J Affect Disord. 2004;78 (2):131–140.
  19. Яхин К. К., Менделевич Д. М. Опросник для выявления и оценки невротических состояний. Метод. рекомен. – Казань, 1978. – 23 с.
  20. Недоступ А. В., Федорова В. И., Линевич А. Ю. и др. Тревожно-депрессивные и нейромедиаторные нарушения у больных гипертонической болезнью, влияние на них терапии ципрамилом. Терапевтический архив. 2005;77 (11):55–62.
  21. Mann JJ, McBride PA, Anderson GM, Mieczkowski TA. Platelet and whole blood serotonin content in depressed inpatients: correlations with acute and life-time psychopathology. Biol Psychiatry. 1992;32 (3):243–257.
Kirillova V. V., Prosviryakov E. Yu. High blood serotonin levels – marker of CHF or depression? Russian Heart Failure Journal. 2012;13(1):36-39

To access this material please log in or register

Register Authorize
Ru En